Phytate levels and bone parameters: A retrospective pilot clinical trial

Frontiers in Bioscience - Elite

Volumn 2 E, Issue 3, 2010, Pages 1093-1098

  Lopez Gonzalez, Angel A ^a   Grases, Felix ^b,c   Perello, Joan ^b,c   Tur, Fernando ^b,c   Costa Bauza, Antonia ^b,c   Monroy, Nieves ^d   Mari, Bartolome ^e   Vicente Herrero, Teofila ^f  

^a Servicio de Prevencion de Riesgos Laborales   (Spain)

^b UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Administracion de les Illes Balears   (Spain)

^e Servicio de Medicina Del Deporte ^*  (Spain)

^f Servicio Medico   (Spain)

Author keywords

Bone Mineral Density; Clinical Trial; Osteoporosis; Phytate

Indexed keywords

PHYTIC ACID;

ARTICLE; BONE DENSITY; CLINICAL TRIAL; FEMALE; HUMAN; MIDDLE AGED; PILOT STUDY; POSTMENOPAUSE; RETROSPECTIVE STUDY; URINE;

BONE DENSITY; FEMALE; HUMANS; MIDDLE AGED; PHYTIC ACID; PILOT PROJECTS; POSTMENOPAUSE; RETROSPECTIVE STUDIES;

EID: 77957365809     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. South Med J, 94(6), 569-73 (2001)
2. A. A. Lopez-Gonzalez, F. Grases, P. Roca, B. Mari, M. T. Vicente-Herrero and A. Costa-Bauza: Phytate (myo- Inositol Hexaphosphate) and Risk Factors for Osteoporosis. Journal of Medicinal Food, 11(4), 747-752 (2008) doi:doi:10.1089/jmf.2008.0087
3. F. Grases, B. Isern, P. Sanchis, J. Perello, J. J. Torres and A. Costa-Bauza: Phytate acts as an inhibitor in formation of renal calculi. Frontiers in Bioscience, 12, 2580-2587 (2007)
4. F. Grases, R. M. Prieto, B. M. Simonet and J. G. March: Phytate prevents tissue calcifications in female rats. Biofactors, 11(3), 171-177 (2000) (Pubitemid 30365965)
5. A. Conte, P. Piza, A. Garcia-Raja, F. Grases, A. Costa- Bauza and R. M. Prieto: Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate). Arch Esp Urol, 52(3), 305-10 (1999) (Pubitemid 29230379)
6. F. Grases, R. Garcia-Gonzalez, J. J. Torres and A. Llobera: Effects of phytic acid on renal stone formation in rats. Scandinavian Journal of Urology and Nephrology, 32(4), 261-265 (1998) (Pubitemid 28387176)
7. G. C. Curhan, W. C. Willett, E. L. Knight and M. J. Stampfer: Dietary factors and the risk of incident kidney stones in younger women - Nurses' health study II. Archives of Internal Medicine, 164(8), 885-891 (2004) (Pubitemid 38520630)
8. F. Grases, J. G. March, R. M. Prieto, B. M. Simonet, A. Costa-Bauza, A. Garcia-Raja and A. Conte: Urinary phytate in calcium oxalate stone formers and healthy people - Dietary effects on phytate excretion. Scandinavian Journal of Urology and Nephrology, 34(3), 162-164 (2000) (Pubitemid 32055263)
9. F. Grases, P. Sanchis, J. Perello, B. Isern, R. M. Prieto, C. Fernandez-Palomeque, M. Fiol, O. Bonnin and J. J. Torres: Phytate (Myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats. Frontiers in Bioscience, 11, 136-142 (2006) (Pubitemid 43253481)
10. F. Grases, P. Sanchis, J. Perello, B. Isern, R. M. Prieto, C. Fernandez-Palomeque and C. Saus: Phytate reduces agerelated cardiovascular calcification. Frontiers in Bioscience, 13, 7115-7122 (2008)
11. F. Grases, P. Sanchis, J. Perello, B. Isern, R. M. Prieto, C. Fernandez-Palomeque and J. J. Torres: Effect of crystallization inhibitors on vascular calcifications induced by vitamin D - A pilot study in Sprague-Dawley rats. Circulation Journal, 71(7), 1152-1156 (2007) (Pubitemid 46998036)
12. F. Grases, P. Sanchis, A. Costa-Bauza, O. Bonnin, B. Isern, J. Perello and R. M. Prietoa: Phytate inhibits bovine pericardium calcification in vitro. Cardiovascular Pathology, 17(3), 139-145 (2008) doi:10.1016/j.carpath.2007.08. 005 (Pubitemid 351626940)
13. F. Grases, C. Santiago, B. M. Simonet and A. Costa- Bauza: Sialolithiasis: mechanism of calculi formation and etiologic factors. Clinica Chimica Acta, 334(1-2), 131-136 (2003) (Pubitemid 36836066)
14. F. Grases, J. Perello, P. Sanchis, B. Isern, R. M. Prieto, A. Costa-Bauza, C. Santiago, M. L. Ferragut and G. Frontera: Anticalculus effect of a triclosan mouthwash containing phytate: a double-blind, randomized, three-period crossover trial. Journal of Periodontal Research, 44(5), 616-621 (2009)
15. D. C. Harrison and E. Mellanby: Phytic acid and the rickets-producing action of cereals. Biochemical Journal, 33, 1660-U1 (1939)
16. P. H. Henneman, P. H. Benedict, A. P. Forbes and H. R. Dudley: Idiopathic hypercalcuria. New England Journal of Medicine, 259(17), 802-807 (1958)
17. A. R. P. Walker, F. W. Fox and J. T. Irving: Studies in human mineral metabolism .1. the effect of bread rich in phytate phosphorus on the metabolism of certain mineral salts with special reference to calcium. Biochemical Journal, 42(3), 452-462 (1948)
18. H. Cullumbine, V. Basnayake, J. Lemottee and T. W. Wickramanayake: Mineral metabolism on rice diets. British Journal of Nutrition, 4(2-3), 101-111 (1950)
19. A. M. Shamsuddin, J. A. Von Fraunhofer and F. J. A. Von: Decreasing titratable acidity of foodstuff or beverage, e.g. nutrient-enriched drinks, used to treat and prevent degeneration of teeth and other bones, involves depositing inositol phosphate composition into foodstuff or beverage. In: Ip-6 Res Inc; Shamsuddin A M; Von Fraunhofer J A, (2007)
20. M. Arrabal, Diaz de la Guardia, F., A. Jimenez, V. Lopez, M. A. Arrabal and A. Zuluaga: Tratamiento de la litiasis renal con bisfosfonatos. Arch. Esp. Urol., 60, 745- 754 (2007)
21. P. A. Price, S. A. Faus and M. K. Williamson: Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arteriosclerosis Thrombosis and Vascular Biology, 21(5), 817-824 (2001) (Pubitemid 32448773)
22. M. C. Hochberg and R. Rizzoli: Long-term experience with alendronate in the treatment of osteoporosis (vol 7, pg 1201, 2006). Expert Opinion on Pharmacotherapy, 7(12), 1683-1683 (2006)
23. J. Iwamoto, T. Takeda and Y. Sato: Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Current Medical Research and Opinion, 22(5), 919-928 (2006) (Pubitemid 43875559)
24. H. Hagino, Y. Nishizawa, T. Sone, H. Mori, Y. Taketani, T. Nakamura, A. Itabashi, H. Mizunuma, Y. Ohashi, M. Shiraki, T. Minamide and T. Matsumoto: A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone, 44(6), 1078-1084 (2009)
25. J. P. Bilezikian: Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis. American Journal of Medicine, 122(2), 14-21 (2009)
26. R. Bize, O. Lamy and I. Peytremann-Bridevaux: Osteoporotic fracture in menopausal women: alendronate reduces the risk. Rev Med Suisse, 4(183), 2703 (2008)
27. J. Iwamoto, Y. Sato, T. Takeda and H. Matsumoto: Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. Clin Interv Aging, 3(3), 483-9 (2008)
28. K. K. Holder and S. S. Kerley: Alendronate for fracture prevention in postmenopause. American Family Physician, 78(5), 579-581 (2008)
29. F. Lanza, H. Schwartz, B. Sahba, H. M. Malaty, T. Musliner, R. Reyes, H. Quan and D. Y. Graham: An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. American Journal of Gastroenterology, 95(11), 3112-3117 (2000)
30. C. A. Migliorati, J. Casiglia, J. Epstein, P. L. Jacobsen, M. A. Siegel and S. B. Woo: Managing the care of patients with bisphosponate-associated osteonecrosis - An American Academy of Oral Medicine position paper. Journal of the American Dental Association, 136(12), 1658-1668 (2005) (Pubitemid 41810027)
31. F. Grases, J. Perello, B. Isern and R. M. Prieto: Determination of myo-inositol hexakisphosphate (phytate) in urine by inductively coupled plasma atomic emission spectrometry. Analytica Chimica Acta, 510(1), 41-43 (2004) (Pubitemid 38759032)
32. A. A. Lopez-Gonzalez, F. Grases Freixedas, A. Costa Bauza, N. Monroy, M. T. Vicente-Herrero and M. A. Jaume: Fitato y su utilidad en la practica clinica. Medicina Balear, 24, 39-46 (2009)
33. A. Millan, M. Pavelkova, O. Sohnel and F. Grases: Inhibition of calcium oxalate monohydrate crystal growth in high and low ionic strength solutions. Crystal Research and Technology, 33(5), 777-786 (1998) (Pubitemid 128665378)
34. F. Grases and J. G. March: Adsorption processes during crystalline growth - an analytical tool. Trac-Trends in Analytical Chemistry, 10(6), 190-195 (1991)
35. G. A. Rodan and H. A. Fleisch: Bisphosphonates: Mechanisms of action. Journal of Clinical Investigation, 97(12), 2692-2696 (1996) (Pubitemid 26197084)
36. M. J. Rogers: New insights into the molecular mechanisms of action of bisphosphonates. Current Pharmaceutical Design, 9(32), 2643-2658 (2003) (Pubitemid 37456015)
37. R. G. G. Russell: Bisphosphonates: Mode of action and pharmacology. Pediatrics, 119, S150-S162 (2007) (Pubitemid 46397937)
38. F. Grases, B. M. Simonet, J. G. March and R. M. Prieto: Inositol hexakisphosphate in urine: the relationship between oral intake and urinary excretion. Bju International, 85(1), 138-142 (2000) (Pubitemid 30072465)
39. F. Grases, B. M. Simonet, I. Vucenik, R. M. Prieto, A. Costa-Bauza, J. G. March and A. M. Shamsuddin: Absorption and excretion of orally administered inositol hexaphosphate (IP6 or phytate) in humans. Biofactors, 15(1), 53-61 (2001) (Pubitemid 34014664)
40. F. Grases, B. M. Simonet, R. M. Prieto and J. G. March: Phytate levels in diverse rat tissues: influence of dietary phytate. British Journal of Nutrition, 86(2), 225-231 (2001) (Pubitemid 32780628)